AI Platform Connects Nearly 300 Duchenne Patients to Clinical Trials and Expanded Access Programs
核心洞察
myTomorrows (搜索) announced it has referred 611 Duchenne muscular dystrophy (搜索) patients to clinical trials and expanded access programs using its AI-powered precision matching platform, with nearly 300 successfully enrolled.
The company's AI-driven platform automates clinical trial matching with up to 98% accuracy, addressing significant barriers where only 33% of US Duchenne patients have previously participated in clinical trials.
Patient Navigators conducted over 5,000 multilingual support calls in 2024 alone, providing personalized guidance to families navigating the rare genetic disorder that causes progressive muscle weakness primarily in boys.
myTomorrows (搜索), a global health technology company, has successfully referred 611 patients with Duchenne muscular dystrophy (搜索) (DMD) to clinical trials and expanded access programs worldwide using its AI-powered precision matching platform, with nearly 300 patients successfully enrolled. The announcement comes ahead of World Duchenne Awareness Day, highlighting the significant impact of artificial intelligence and tailored patient navigation in improving access for rare disease communities.
Addressing Critical Access Barriers
Duchenne muscular dystrophy (搜索) is a rare genetic disorder that causes progressive muscle weakness and deterioration, primarily affecting boys, with symptoms typically beginning between ages two and three. Despite the urgent need for research participation, significant barriers persist in accessing clinical trials. Among the US population, only 33% of those with Duchenne have previously participated in a clinical trial.
According to myTomorrows (搜索)' recent survey of healthcare professionals, 56% of physicians report that the clinical trial referral process is fragmented and slow, while 72% find searching for trials too time-consuming. These challenges are particularly significant for Duchenne muscular dystrophy (搜索), where the number of available trials is limited and timely referrals are essential for patient access.
AI-Powered Precision Matching
myTomorrows (搜索)' AI-driven platform automates clinical trial matching with up to 98% accuracy, easing the recruitment burden for sponsors and research sites. The platform helps Duchenne patients and their physicians overcome the logistical and administrative barriers that often delay access to emerging therapies. By rapidly sourcing and analyzing data from global public trial registries, the platform aligns patient profiles with complex eligibility criteria in minutes, identifying relevant clinical trials worldwide.
The company pairs the accuracy and efficiency of AI with dedicated Patient Navigators to provide the personal guidance families need when facing a challenging diagnosis such as Duchenne. In 2024 alone, myTomorrows (搜索) Patient Navigators conducted over 5,000 multilingual support calls, guiding patients and their families through each step of treatment discovery and access. Their global team spans the Americas, Asia Pacific, Europe, Africa, and the Middle East, ensuring critical support for patients worldwide.
Expanding Neuromuscular Disease Support
Building on deep expertise in the neuromuscular disease space, myTomorrows (搜索) currently runs more than 20 clinical trial recruitment or expanded access programs with BioPharma sponsors in this therapeutic area, underscoring its commitment to advancing therapies in rare diseases. The company is also recognized as an expert in neurodegenerative diseases, providing patient navigation support for patients with amyotrophic lateral sclerosis (搜索) (ALS), Parkinson's disease (搜索), and Multiple System Atrophy (搜索) (MSA).
"As both a Duchenne patient advocate and a consultant with myTomorrows (搜索), I've seen first-hand the challenges families face when navigating this disease and searching for treatment options," said Terri Ellsworth. "Without clinical trial participation, we cannot advance progress and innovation in the life sciences. My son is living proof. His 5+ year study participation helped support the first ever FDA Duchenne drug approval which paved the way for future developments."
Leadership Perspective
"We are incredibly proud to support rare diseases communities like Duchenne, where patients and families face enormous challenges and limited treatment options," said Michel van Harten, MD, CEO of myTomorrows (搜索). "Today, we're celebrating not just matching Duchenne patients to emerging therapies but actually referring and enrolling hundreds of them in clinical trials and expanded access programs. Every referral and enrollment represent a person and their family navigating a profoundly difficult path forward, and we're honored to stand alongside them."
Platform Capabilities and Reach
myTomorrows (搜索)' secure, compliant platform meets ISO 27001, GDPR SOC 2, and HIPAA standards and integrates seamlessly with electronic health records to deliver precise and actionable results. The company has built proprietary technology that conducts comprehensive and accurate searches of clinical trials and expanded access programs from global public registries.
Headquartered in Amsterdam with an office in New York City, myTomorrows (搜索) has helped more than 16,200 patients and 2,600 physicians across 290+ sites in over 133 countries. The company regularly participates in leading international conferences in the neuromuscular and neurodegenerative space, collaborating with patient advocacy groups to raise awareness about unmet medical needs and education around clinical trial participation.